PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Kenyan Antihypertensive Market Driven by Economic Growth and Lifestyle Changes - The Kenyan antihypertensive market is growing at 5.5 per cent a year, driven by better economic prospects and lifestyle changes among a prospering middle class
Kenyan Antihypertensive Market Driven by Economic Growth and Lifestyle Changes

 

NewswireToday - /newswire/ - Cape Town, South Africa, 2008/05/30 - The Kenyan antihypertensive market is growing at 5.5 per cent a year, driven by better economic prospects and lifestyle changes among a prospering middle class.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

However, the increasing entry of generic drug manufacturing firms is threatening the market share of big pharmaceutical companies.

New analysis from Frost & Sullivan (pharma.frost.com), Strategic Analysis of the Kenyan Hypertension Markets, finds that the market earned revenues of $26.0 million in 2007 and estimates this to reach $34.0 million in 2012.

"The rise of the middle class and drastic changes in their lifestyle has led to a sharp increase in the number of cases recorded in the past few years," notes Frost & Sullivan Research Analyst Lizelle Wentzel. "At the same time, many more patients can seek treatment due to having better access to healthcare services and health insurance from their workplaces."

ACE inhibitors are the most commonly used active ingredient because of their low prices. While public hospitals normally offer ACE inhibitors and diuretics because they are cheaper, diuretics and centrally acting anti-hypertensive drugs are not produced by the market leaders due to profitability issues. There is also a growing trend towards calcium channel blockers, which are found to be highly effective.

However, price cutting by generic firms is proving to be a major challenge for ethical drug manufacturers. Moreover, there is insufficient patent protection for ethical drug manufacturers and therefore generics enter the market soon after the ethical drug has gained acceptance.

"Generic drugs are gaining market share through volumes and are favoured for government tenders because of their low price," says Wentzel. "It is also common to find a generic entering the Kenyan hypertension market before the ethical drug."

Given this challenge, a price floor may well be required to prevent further price drops and maintain market attractiveness.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an outline of the strategic analysis of the Kenyan hypertension markets, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Strategic Analysis of the Kenyan Hypertension Markets is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: Emerging Therapies for Diabetes (Technical Insights), U.S. Heart Failure Therapeutics Markets and Digital Blood Pressure Meters Digital Thermometers and Nebulizer Markets in Indonesia. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Strategic Analysis of the Kenyan Hypertension Markets M1F6

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Kenyan Antihypertensive Market Driven by Economic Growth and Lifestyle Changes

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)